Azo curcumin II for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 500+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 220+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
Azo curcumin II may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 500+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
220+ treatments.
We have not reviewed azo curcumin II in detail.
, Harnessing the Antiviral Potential of Hypothetical Azo Curcumins: A Computational Docking Exploration Targeting the Main Protease of SARS-CoV-2, Turkish Computational and Theoretical Chemistry, doi:10.33435/tcandtc.1717989
The global health crisis precipitated by COVID-19, caused by severe acute respiratory syndrome-Coronavirus 2 (SARS-CoV-2), has spurred an urgent quest for effective therapeutic interventions. Several repurposed drugs, including chloroquine, hydroxychloroquine, ivermectin, artemisinin, remdesivir, and azithromycin, have been explored for their antiviral potential. Amid this pharmacological landscape, curcumin—a natural polyphenolic compound renowned for its broad-spectrum bioactivity—has emerged as a promising candidate in the fight against COVID-19. Recent investigations into curcumin analogues and derivatives further underscore its therapeutic versatility. This study seeks to unravel the molecular interactions of hypothetical azo curcumins and hydroxychloroquine with the SARS-CoV-2 main protease, employing molecular docking and computational analysis to elucidate their binding affinities and mechanistic insights. By leveraging advanced computational techniques, this research endeavours to provide a deeper understanding of these molecules' antiviral potential, paving the way for future pharmacological developments in combating SARS-CoV-2.